drugset / Trial / NCT01631318
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Completed
34 enrolled
Stanford University
National Cancer Institute (NCI) · collabPhilips Healthcare · collab
NaSingle-groupOpen-labelDiagnostic
Summary
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Timeline
- Start
- 2012-11-01
- Primary completion
- 2020-08-31
- Completion
- 2020-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Definity | Diagnostic / imaging agent | 0.4 ml | Intravenous |